Omeros Stock Plunges 17% After Earnings And Plans To Curb Its Free-Drug Program
Drug sales rose 26% from the second quarter, but non-cash valuation losses left Omeros with a reported loss.
Omeros, which develops protein and small-molecule medicines, plunged 17% in Tuesday trading following Monday's earnings release and call. Management said it plans to stop enrolling new patients in its international free-drug program while finishing treatment for patients already participating.
Sales Growth Meets A Reported Loss
OMER shares fell 17.1% to $13.83 in Tuesday trading, as of 9:44 AM ET, erasing $206 million in market value. The company was worth about $1 billion and was on pace for its fourth straight daily decline.
YARTEMLEA generated $35.9 million in third-quarter net sales, up 26% from the second quarter. The $1.8 million previously recorded in adjusted income was below the latest total of $4.7 million.
The reported bottom line was a $57.4 million loss, including $62.0 million of non-cash valuation losses. Most of those valuation losses came from a financial instrument tied to debt that can convert into shares.
Gregory A. Demopulos, Omeros' chairman and CEO, said: "That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow."
An Overseas Approval Setback
Omeros' effort to expand paid access overseas has encountered resistance from European regulators. European Medicines Agency advisers reaffirmed their negative opinion on approval of narsoplimab in October, after reconsidering the decision they reached in June.
The plan to halt new enrollment in the international free-drug program preserves treatment for existing patients. Management said those patients will complete their treatment.
A Commercial Launch And A Sliding Stock
YARTEMLEA is Omeros' one commercial product. It treats TA-TMA, a complication of stem cell transplants, in patients aged two and older. The FDA approved it on December 23, 2025, and sales started in January 2026.
Omeros sells the treatment in the United States through its own sales team working with transplant centers. Its drug development focuses include diseases involving the complement system, part of the immune system, as well as cancers and addictive or compulsive disorders.
The stock entered Tuesday already below its past-year peak. At Monday's close, shares were down 3% for the year, against a 9% gain for the S&P 500, and 21% below their highest close of the past year.
Omeros anticipates starting studies of YARTEMLEA for severe respiratory distress and prevention of transplant complications in late 2026 or early 2027, pending ethics approvals.
Sources
- Omeros: Q3 Earnings Snapshot – WTOP News — wtop.com
- ex_1011405.htm — sec.gov
- Omeros Corp. (NASDAQ:OMER) : Articles :: Law360 — law360.com
- Omeros: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Omeros Corporation Reports Third Quarter 2026 Financial Results — businesswire.com
- The company's filing (Omeros) — SEC filing
- Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates — Zacks Investment Research
- Omeros — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR